GlassScriptPhysician profile
Jose M Sanchez
NPI 1942258355
$3,761.12
in general payments reported to CMS, 2019-2025
17 companies · $835 in 2025
The $835 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $138 · 2021: $286 · 2022: $544 · 2023: $651 · 2024: $1,010 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,134 · Gift: $327 · Education: $34.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.98 |
| Gift | $327.24 |
| Education | $34.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $1,554.17 | 2021-2025 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $832.55 | 2020-2025 | Sutab, Suflave |
| Abbvie INC. | $374.46 | 2020-2025 | Rinvoq, Skyrizi |
| Medtronic Vascular, INC. | $218.26 | 2019 | |
| Redhill Biopharma INC. | $172.78 | 2020-2024 | Talicia |
| Ardelyx, INC. | $163.64 | 2024-2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $94.80 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.69 | 2019 | |
| Janssen Biotech, INC. | $56.42 | 2022-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $52.47 | 2024 | Voquezna |
| Lilly USA, LLC | $45.36 | 2025 | Omvoh |
| Aimmune Therapeutics, INC. | $41.52 | 2024 | |
| Celgene Corporation | $34.00 | 2022 | |
| Tactile Systems Technology INC | $23.77 | 2024 | Entre Plus, Flexitouch Plus |
| Evoke Pharma, INC. | $17.76 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $11.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.